Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study

Results. The AYA BT survivors had an increased risk for late-appearing endocrine diseases (HR, 2.9; 95% CI, 1.1‐8.0), psychiatric disorders (HR, 2.0; 95% CI, 1.2‐3.2), diseases of the nervous system (HR, 9; 95% CI, 6.6‐14.0), disorders of vision/hearing loss (HR, 3.6; 95% CI, 1.5‐8.5), diseases of the circulatory system (HR, 4.9; 95% CI, 2.9‐8.1), and diseases of the kidney (HR, 5.9; 95% CI, 2.5‐14.1). Survivors with irradiation had an increased risk for diseases of the nervous system compared with non-irradiated survivors (HR, 3.3; 95% CI, 1.8‐6.2). The cumulative prevalence for most of the diagnoses remained significantly increased for survivors even 20 years after cancer diagnosis. Conclusions. The AYA BT survivors have an increased risk of morbidity for multiple new outcomes for ≥5 years after their primary diagnosis. This emphasizes the need for structured late-effect follow-up for this patient group.